Home › Free Stock Grades › CLDX
Celldex Therapeutics, Inc. (CLDX) Stock Grade
CLDX · Healthcare
C
Market Cap
$2.1B
P/E Ratio
—
Revenue Growth (YoY)
-78.6%
Net Margin
-17253.3%
Return on Equity
—
Dividend Yield
None
About Celldex Therapeutics, Inc.'s fundamentals
Celldex Therapeutics is a $2.1 billion biotechnology company that reported a dramatic 78.6% year-over-year revenue decline in its latest period, reflecting a significant contraction in commercial activity. The company posted a substantial net loss, resulting in a net margin of -17253.3%, indicating that expenses far exceeded revenues. As a pre-profitability biotech firm, traditional valuation metrics like P/E ratio and return on equity are not applicable, and the company does not currently pay dividends.